Human Allogeneic iPSC-derived Dopaminergic Neural Progenitor Cell Injection in Early-onset Parkinson's Disease
Parkinson Disease
Enrolment: 90 · Results not recorded
Loading the evidence…
Biologic · Cell therapy; no ChEMBL entity queried as no defined chemical entity exists. CLASS-LEVEL trial match: recorded trials are iPSC-derived dopaminergic neural progenitor products in Parkinson's disease and MSA-P, not the specific research construct and not a trauma indication. NCT03635294 (iPSC generation from blood samples for rare intellectual disability diagnosis) rejected as a diagnostic study with no cell therapy.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Parkinson Disease
Enrolment: 90 · Results not recorded
Multiple System Atrophy, Parkinsonian Variant
Enrolment: 3 · Results not recorded
Parkinson Disease
Enrolment: 48 · Results not recorded
Parkinson's Disease
Enrolment: 12 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Acute head-only cranial irradiation at 10 Gy causing cognitive impairment
Grafted animals showed improved spatial memory and contextual fear conditioning versus irradiated sham-surgery controls, with the best performance when grafting was delayed to 4 weeks after irradiation. Grafted cells migrated through CA1 and CA3 and differentiated into neuronal (about 39%) and astr…
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.